Base Genomics launches and raises $11 million USD to progress development of its TAPS technology
Epigenetics company Base Genomics has launched with a team of leading scientists and clinicians to set a new gold standard in DNA methylation detection. The company has closed an oversubscribed seed funding round of $11 million USD (£9 million GBP) to progress the development of its TAPS technology, initially focusing on developing a blood test for early-stage cancer and minimal residual disease.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063